Masimo Corp (MASI) rolled out the red carpet Wednesday for investors, hosting its 2025 Investor Day and painting a picture of what the medical device company expects to look like three years from now. The short version? Bigger revenues, fatter margins, and a lot more cash generation.
The company's management team walked through its long-term strategy and updated projections through 2028. They're targeting revenue growth of 7-10% annually, which would represent solid, steady expansion in the medical technology space. But the real headline is on the profitability side: Masimo expects operating margins to climb to around 30% by 2028.
That margin expansion tells an important story about the business maturing and achieving scale. Management is projecting adjusted earnings per share will hit $8.00 by 2028, a meaningful jump from current levels. Over the three-year period from 2026 through 2028, the company expects to generate roughly $1 billion in cumulative operating cash flow, which should give them plenty of flexibility for investments or returning capital to shareholders.
For the more immediate future, Masimo reaffirmed its previously announced 2025 guidance. The company still expects revenue between $1.51 million and $1.53 million, operating profit of $412 million to $424 million, and earnings per share in the $5.40 to $5.55 range.
"Masimo's market-leading position is driven by our mission to deliver innovations that empower clinicians and transform patient care," said Katie Szyman, Chief Executive Officer of Masimo. "As we enter this next chapter, we are incredibly well-positioned to advance that mission."
Wall Street Responds
BTIG clearly liked what they heard. The firm maintains its Buy rating on Masimo and bumped up its price target from $198 to $200.
The Apple Win That Keeps Giving
It's worth remembering that Masimo scored a major legal victory recently. Back in November, a federal jury in California ruled that Apple Inc. (AAPL) must pay Masimo $634 million for infringing a patent related to blood-oxygen reading technology. That's real money, and it validates Masimo's intellectual property position in a space where Apple has been trying to build out health monitoring features.
Recent Performance Backs Up the Optimism
The bullish outlook isn't coming out of nowhere. Masimo reported third-quarter adjusted earnings of $1.32 per share, comfortably beating the consensus estimate of $1.20. Revenue came in at $371.2 million, topping expectations of $366.85 million.
Following those results, the company raised its fiscal 2025 adjusted earnings guidance from $5.45-$5.70 per share to $5.62-$5.79, compared to the Wall Street consensus of $5.33. They did narrow the revenue outlook slightly, from $1.51 billion-$1.54 billion to $1.51 billion-$1.53 billion, but that's still right in line with the consensus of $1.52 billion.
MASI Price Action: Masimo shares were up 0.25% at $138.44 at the time of publication on Thursday.